Company Filing History:
Years Active: 2013-2015
Title: Simon Stacey: Innovator in Breast Cancer Risk Assessment
Introduction
Simon Stacey is a notable inventor based in Kopavogur, Iceland. He has made significant contributions to the field of genetics, particularly in the area of breast cancer risk assessment. With a total of two patents to his name, Stacey's work focuses on identifying genetic variants that can help in the diagnosis and management of breast cancer.
Latest Patents
Stacey's latest patents include groundbreaking inventions related to genetic variants for breast cancer risk assessment. The first patent pertains to certain genetic variants that have been identified as susceptibility variants for breast cancer. This invention describes methods for diagnosing increased susceptibility to breast cancer, predicting responses to therapy, and forecasting prognosis using these variants. Additionally, it includes the development of kits that are useful in implementing these methods.
The second patent focuses on genetic variants located on chromosomes 5p12 and 10q26, which are also recognized as susceptibility variants for breast cancer. Similar to the first patent, this invention outlines methods for diagnosing both increased and decreased susceptibility to breast cancer, predicting therapy responses, and assessing prognosis. It also encompasses the creation of kits that facilitate these methods.
Career Highlights
Simon Stacey is currently associated with Decode Genetics Ehf, a company that specializes in genetic research and innovation. His work at Decode Genetics has allowed him to explore the intricate relationships between genetics and disease, particularly in the context of breast cancer.
Collaborations
Stacey has collaborated with notable colleagues such as Patrick Sulem and Andrei Manolescu. These partnerships have likely contributed to the advancement of his research and the successful development of his patents.
Conclusion
In summary, Simon Stacey is a prominent inventor whose work in genetic variants for breast cancer risk assessment has the potential to significantly impact disease management and patient outcomes. His contributions to the field are marked by innovative patents and collaborations with esteemed colleagues.